Demand for general anesthesia drugs will increase through 2036, with propofol at 35.0% of the drug class segment in 2026, driven by surgical procedure volume growth and expanding surgical infrastructure. The market was valued at USD 5.20 billion in 2025 and is expected to be worth USD 7.12 billion by 2036.